Document is current
Any future updates will be listed below
-
Authors
Matsumoto, Minako
Kumazawa, Ryosuke
Ishii-Watabe, Akiko
Horiguchi, Itsuko
Mamiya, Hiroaki
Shibata, Hiroko
Saito, Yoshiro
Adomi, Motohiko
Taniguchi, Yuta
Komiyama, Jun
Sakai, Ryoko
Iwagami, Masao
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour, and Welfare Policy Research Grants (202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A, 202406039A)
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 25 July 2025
First Online: 7 August 2025
Declarations
:
: HM received consulting fees from GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Biogen Japan Ltd., Takeda Pharmaceutical Co., Ltd., TEIJIN Pharma Ltd., Hisamitsu Pharmaceutical Co., Inc., and Otsuka Pharmaceutical Co., Ltd. RS received consulting fees from Nippon Kayaku Co. Ltd. MI’s Department of Digital Health, Institute of Medicine, University of Tsukuba, is conducting joint research with JMDC Inc., with funding from JMDC Inc. The funders played no role to conduct the present study.
